Chitogenx Stock Performance
CHNXF Stock | USD 0.01 0.00 0.00% |
The firm shows a Beta (market volatility) of -3.98, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning ChitogenX are expected to decrease by larger amounts. On the other hand, during market turmoil, ChitogenX is expected to outperform it. At this point, ChitogenX has a negative expected return of -0.16%. Please make sure to confirm ChitogenX's coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and day median price , to decide if ChitogenX performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days ChitogenX has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest fragile performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
Begin Period Cash Flow | 2.4 M | |
Total Cashflows From Investing Activities | -33 K |
ChitogenX |
ChitogenX Relative Risk vs. Return Landscape
If you would invest 1.25 in ChitogenX on December 19, 2024 and sell it today you would lose (0.54) from holding ChitogenX or give up 43.2% of portfolio value over 90 days. ChitogenX is currently producing negative expected returns and takes up 10.5647% volatility of returns over 90 trading days. Put another way, 94% of traded otc stocks are less volatile than ChitogenX, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
Risk |
ChitogenX Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ChitogenX's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as ChitogenX, and traders can use it to determine the average amount a ChitogenX's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.015
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | CHNXF |
Estimated Market Risk
10.56 actual daily | 94 94% of assets are less volatile |
Expected Return
-0.16 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average ChitogenX is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ChitogenX by adding ChitogenX to a well-diversified portfolio.
ChitogenX Fundamentals Growth
ChitogenX OTC Stock prices reflect investors' perceptions of the future prospects and financial health of ChitogenX, and ChitogenX fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ChitogenX OTC Stock performance.
Return On Asset | -2.92 | |||
Current Valuation | 12.49 M | |||
Shares Outstanding | 51.04 M | |||
EBITDA | (3.72 M) | |||
Cash And Equivalents | 2.19 M | |||
Cash Per Share | 0.04 X | |||
Total Debt | 4.78 M | |||
Book Value Per Share | (0.15) X | |||
Cash Flow From Operations | (3.22 M) | |||
Total Asset | 1.12 M | |||
About ChitogenX Performance
By analyzing ChitogenX's fundamental ratios, stakeholders can gain valuable insights into ChitogenX's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ChitogenX has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ChitogenX has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada. ChitogenX Inc. was incorporated in 2015 and is headquartered in Kirkland, Canada. Chitogenx is traded on OTC Exchange in the United States.Things to note about ChitogenX performance evaluation
Checking the ongoing alerts about ChitogenX for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for ChitogenX help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.ChitogenX generated a negative expected return over the last 90 days | |
ChitogenX has high historical volatility and very poor performance | |
ChitogenX has some characteristics of a very speculative penny stock | |
ChitogenX has a very high chance of going through financial distress in the upcoming years | |
Net Loss for the year was (4.92 M) with profit before overhead, payroll, taxes, and interest of 0. | |
ChitogenX has accumulated about 2.19 M in cash with (3.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Roughly 17.0% of the company shares are held by company insiders | |
Latest headline from simplywall.st: Disposition of 400000 shares by Hackman Jeffrey S. of Fennec Pharmaceuticals at 5.58 subject to Rule 16b-3 |
- Analyzing ChitogenX's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ChitogenX's stock is overvalued or undervalued compared to its peers.
- Examining ChitogenX's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ChitogenX's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ChitogenX's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of ChitogenX's otc stock. These opinions can provide insight into ChitogenX's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ChitogenX OTC Stock analysis
When running ChitogenX's price analysis, check to measure ChitogenX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ChitogenX is operating at the current time. Most of ChitogenX's value examination focuses on studying past and present price action to predict the probability of ChitogenX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ChitogenX's price. Additionally, you may evaluate how the addition of ChitogenX to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |